Yusuke Nakamura to Circulating Tumor DNA
This is a "connection" page, showing publications Yusuke Nakamura has written about Circulating Tumor DNA.
Connection Strength
1.683
-
Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy? Clin Chem. 2020 07 01; 66(7):946-957.
Score: 0.719
-
Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. Int J Mol Sci. 2022 Sep 29; 23(19).
Score: 0.210
-
Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer Sci. 2022 May; 113(5):1808-1820.
Score: 0.202
-
Clinical implementation and current advancement of blood liquid biopsy in cancer. J Hum Genet. 2021 Sep; 66(9):909-926.
Score: 0.192
-
Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Cancer Sci. 2021 Jan; 112(1):454-464.
Score: 0.184
-
Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Apr; 180(2):331-341.
Score: 0.175